Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT01976260
Other study ID # STU84041
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date October 2013
Est. completion date December 2024

Study information

Verified date March 2024
Source Northwestern University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to compare the effectiveness of the ePrime fractional radiofrequency system to the 1550-nm fractional photothermolysis system (Fraxel) in the ability to improve acne scar appearance.


Description:

Participants in this study will be patients at the dermatology clinic with icepick and boxcar acne scars on at least one 2 x 2 cm area on each side of face. Subjects will be randomly assigned to receive fractional radiofrequency treatment to either the right or left side of the face and the contralateral side will receive 1550-nm fractional photothermolysis. Subjects will receive treatments at baseline, week 4, and week 8 for a total of three treatments. Follow up visits will take place at week 16, two months following the last treatment visit. This study is a pilot study designed to determine feasibility of these procedures.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 16
Est. completion date December 2024
Est. primary completion date December 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: 1. Subjects age 18 years and older. 2. Subjects with bilateral 2x2 cm areas of ice pick and/or boxcar acne scars on their face. 3. Subjects are in good health. 4. Subjects have the willingness and the ability to understand and provide informed consent and communicate with the investigator. Exclusion Criteria: 1. Subjects who have received injectable soft-tissue augmentation materials to the face, or facial ablative resurfacing, within the past 6 months. 2. Subjects who have received injectable botulinum toxin to the face, or any nonablative laser treatment to the face, within the past 3 months. 3. Subjects who have local infections, open facial wounds, or other significant local skin disease that would interfere with acne scar treatment with energy devices. 4. Subjects who are allergic to lidocaine or prilocaine. 5. Subjects who have a history of abnormal scarring in the treatment area, such as keloid scar formation. 6. Subjects who have ectropion or or other eyelid disfigurement. 7. Subjects who have a history of isotretinoin use in the preceding year. 8. Pregnant or lactating individuals.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Fractional Radiofrequency

1550-nm Fractional Photothermolysis


Locations

Country Name City State
United States Northwestern University Department of Dermatology Chicago Illinois

Sponsors (1)

Lead Sponsor Collaborator
Northwestern University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in best overall cosmetic appearance (right side or left side better)rated by a blinded dermatologist from baseline to week 16 The primary outcome was a blinded rating of the treatment area (Fractional Radiofrequency Versus Fractional Photothermolysis) with the best cosmetic appearance. A dermatologist will blindly evaluate the treated areas of each side from live subjects at baseline and on the final follow up visit (week 16). 1 hour at baseline and week 16
See also
  Status Clinical Trial Phase
Completed NCT02645773 - Early Intervention With Non-ablative Fractional Laser to Reduce Cutaneous Scarring N/A
Completed NCT02672956 - Comparison of Different Umbilical Port Entry Techniques in Terms of Cosmetic Results N/A
Completed NCT00629811 - Improvement in Scar Appearance Following Injection of Avotermin (Juvista) Into Skin Incisions Made in Healthy Men and Women Phase 2
Completed NCT00847795 - Efficacy and Safety of Intradermal RN1001 (Avotermin) in Elderly Subjects. Phase 1/Phase 2
Completed NCT00977951 - Genomic Changes Associated With the Use of Intradermal Avotermin (Juvista) in Small Wounds in Healthy Male Subjects Phase 1/Phase 2
Not yet recruiting NCT03213548 - Aesthetic and Functional Results of Alar Base Modifications in Rhinoplasty N/A
Recruiting NCT05377723 - Abdominal Scar Improvement in Microsurgical Breast Reconstruction N/A
Terminated NCT00432328 - Juvista (Avotermin) in Breast Reduction Surgery Scars Phase 2
Completed NCT00984503 - Investigation of the Accelerated Healing and Anti-scarring Potential of Avotermin (Juvista) in Split Skin Graft Donor Sites Phase 2
Completed NCT00594581 - Anti-Scarring Efficacy and Safety of Intradermal Juvista (Avotermin) in Healthy Males Phase 2
Recruiting NCT04420442 - Scar Resection and Reconstruction With Integra and Split Skin Grafts in Patients With Non-Suicidal Self-Inflicted Scars N/A
Completed NCT02772289 - Perinatal Tissue Mesenchyme Stem Cells in the Treatment for Caesarean Section Scars Phase 2
Completed NCT00430326 - Juvista (Avotermin) in Scars Following Varicose Vein Removal Phase 2
Completed NCT00847925 - Safety and Efficacy of RN1001(Avotermin) in Healthy Male Subjects Phase 1/Phase 2
Recruiting NCT05787171 - Three Sutures With Different Absorption Rates for Lower Abdominal Incision N/A
Completed NCT02985151 - Interventional Study to Evaluate the Appearance of Surgical Scars After Laser Therapy N/A
Completed NCT02340325 - FS2 Safety and Tolerability Study in Healthy Volunteers Phase 1
Active, not recruiting NCT00432211 - Juvista (Avotermin) in the Prevention or Improvement of Scar Appearance Following Scar Revision Surgery. Phase 2
Completed NCT00978302 - Safety Study of Repeated, Escalating Doses of Intradermal Avotermin (Juvista) Phase 1
Withdrawn NCT04034615 - The Long-term Effect of Perinatal Tissue Mesenchyme Stem Cells in the Treatment for Caesarean Section Scars Phase 2